Market Context

The Keytruda Market was valued at USD 30.45 billion in 2025 and is projected to reach USD 68.75 billion by 2034 at a CAGR of 9.5% from 2026 to 2034, according to Polaris Market Research, with a 2026 estimate of USD 33.26 billion. Beyond clinical demand, the report highlights diagnostics, access channels, and intellectual property dynamics as forces that will shape how the market evolves through the forecast period.

Personalized Medicine and Biomarker Testing

Polaris identifies personalized medicine as a key opportunity, supported by biomarker testing for PD-L1, MSI-H, and dMMR. Testing helps match patients to therapy, and the report cites a tissue-free blood test from Adela launched in March 2026 as an example of the diagnostic innovation entering the market. Greater availability of biomarker testing supports more precise patient selection and can strengthen the evidence base for treatment decisions.

The report also lists the expansion of genomic testing infrastructure in hospitals as a trend. As hospitals build in-house capabilities, genomic testing becomes more closely integrated with oncology care pathways, which supports demand for targeted immunotherapy.

How Patients Access Treatment

The report segments the market by distribution channel into hospital pharmacy and specialty pharmacy. Hospital pharmacy is the largest channel, while specialty pharmacy is the fastest-growing, although the page does not provide share or CAGR values for either. Separately, the report's key takeaways show Hospitals & Oncology Centers at about 71.5% in 2025.

By payer, commercial and private payers form the largest segment, while public payers are the fastest-growing. That pairing is notable because the report also flags budget limits in public systems as a restraint on a therapy with multiple treatment cycles and hospital administration costs.

Biosimilar and Patent Scenarios

A distinctive feature of the report is its scenario analysis of pembrolizumab biosimilars. Polaris outlines three paths, none of which carries dates or figures on the page:

- Base scenario: gradual biosimilar entry, with moderate revenue decline through 2034.

- Aggressive erosion: multiple biosimilars and strong price competition, leading to a faster decline before 2034.

- Resilient combination: combination therapy sustains stable demand through 2034.

These scenarios reinforce why the report treats combination use as a lever for resilience, and why competitive rivalry is rated high. Polaris rates the threat of new entrants as low and supplier power, buyer power, and the threat of substitutes as moderate. In November 2025, the FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, as perioperative treatment for cisplatin-ineligible adults, a reminder that label expansions are a key way the franchise defends demand.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/keytruda-market 

Regional Dynamics

North America accounted for about 46.3% in 2025, the largest share, with the report citing about 2 million new US cancer cases in 2024. Europe holds the second-largest share, with Germany, France, and the UK highlighted and an EU population of about 450.6 million, about 22% of whom are aged 65 and above. Asia Pacific is the fastest-growing region, with Southeast Asia recording about 1.15 million new cancer cases in 2022 and 716,116 cancer deaths. The report names high treatment cost as the key restraint across regions, citing multiple treatment cycles, hospital administration, and budget limits in public systems.

Competitive Landscape

The report names Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, AstraZeneca plc, Pfizer Inc., Novartis AG, Sanofi S.A., Johnson & Johnson, GSK plc, Amgen Inc., Eli Lilly and Company, and Regeneron Pharmaceuticals, Inc. among the key players.

Takeaway for Decision Makers

For pharmaceutical companies, diagnostics providers, and health systems, the Polaris findings point to a market where precision testing, channel strategy, and patent planning are as consequential as clinical performance.

Conclusion

The Keytruda Market is expected to remain an important segment of the oncology therapeutics industry due to the continued significance of immunotherapy in cancer treatment. The expanding clinical application of pembrolizumab across multiple cancer types is supporting treatment demand and ongoing research activities. Increasing cancer prevalence, advancements in immuno-oncology, and growing investment in combination therapies are influencing market development. Continued clinical studies and regulatory evaluations are creating opportunities to improve treatment strategies and patient outcomes. However, competition from alternative therapies, biosimilar development, pricing pressures, and patent-related developments may affect future market dynamics. Overall, the market outlook will depend on clinical innovation, treatment accessibility, regulatory approvals, and the evolving competitive landscape.

More Trending Latest Reports By Polaris Market Research:

Financial Leasing Market

U.S. Hearing Aid Dispensers Market

Psychiatric Digital Biomarkers Market

Clindamycin Phosphate Injection Market

U.S. Hearing Aid Dispensers Market

Muscle Stimulator Market

Raw Beetroot Sugar Market

Increasing use of benzenoid across the globe to drive demand

E-Commerce Market